Collagen-binding C-type natriuretic peptide enhances chondrogenesis and osteogenesis

Area of Science:

• Biochemistry
• Orthopedics
• Biotechnology

Background:

• C-type natriuretic peptide (CNP) promotes bone formation but has a short half-life, requiring continuous administration.
• Existing analogs like Vosoritide have systemic distribution, potentially causing adverse effects like hypotension.
• Targeted delivery to collagen-rich tissues is needed to improve CNP's therapeutic efficacy and safety.

Purpose of the Study:

• To develop a novel synthetic protein, CBD-CNP, by fusing a collagen-binding domain (CBD) to CNP.
• To evaluate CBD-CNP's stability, bioactivity, and targeted delivery capabilities.
• To assess CBD-CNP's efficacy in promoting bone elongation, fracture healing, and treating osteoarthritis in preclinical models.

Main Methods:

• Fusion of a collagen-binding domain (CBD) to C-type natriuretic peptide (CNP) to create CBD-CNP.
• Assessment of CBD-CNP stability, collagen-binding ability, and bioactivity.
• In vivo studies using fetal murine tibiae for bone elongation and mouse models for fracture healing and knee osteoarthritis.
• Spatial transcriptomic analysis to identify molecular mechanisms.

Main Results:

• CBD-CNP demonstrated heat stability and retained CNP's bioactivity and collagen-binding capacity.
• CBD-CNP localized to articular cartilage and promoted bone elongation in murine models.
• Treatment with CBD-CNP at fracture sites increased bone mineral content and volume.
• Intra-articular injection of CBD-CNP suppressed subchondral bone thickening in an osteoarthritis model.

Conclusions:

• CBD-CNP offers a promising strategy for targeted, sustained delivery of CNP in collagen-rich tissues.
• This approach overcomes the limitations of CNP's rapid degradation, enhancing chondrogenesis and osteogenesis.
• CBD-CNP represents a potential therapeutic agent for bone regeneration and osteoarthritis treatment.